Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

  • BioLight, 2 Asian Firms Invest $7.2M in Glaucoma Treatment Tech Company IOPtima

Photonics.com
Dec 2015
TEL AVIV, Israel, Dec. 1, 2015 — BioLight Life Sciences Investments Ltd. and two Asia-based venture capital firms will provide $7.2 million in funding to BioLight subsidiary IOPtima Ltd.

Financing will support commercialization and regulatory approval of the IOPtimate system — a minimally invasive surgical ophthalmic device — in the U.S. The CO2 laser-based technology enables the performance of a filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. The procedure provides high efficacy, and allows for reductions in postoperative complications and use of eye drops, according to BioLight.

The system has been sold in Hong Kong, Poland, Hungary, Romania and Peru; distribution agreements are under negotiation in additional countries.

The two venture firms and BioLight will invest $6 million and $1.2 million, respectively, on the basis of a $13.5 million premoney valuation of IOPtima. BioLight will hold approximately 71 percent of IOPtima's issued and outstanding shares. The private placement is expected to close within the next few weeks, subject to standard closing terms.

For more information, visit www.bio-light.co.il.


GLOSSARY
ophthalmology
The branch of medicine involved in the study of the anatomy, functions, diseases and treatments of the eye.
Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.